References
- 1. Ma LY, Chen WW, Gao RL, Liu LS, Zhu ML, Wang YJ, et al. China cardiovascular diseases report 2018: an updated summary. J Geriatr Cardiol. 2020;17(1):1-8.
- 2. Choo EH, Kim PJ, Chang K, Ahn Y, Jeon DS, Lee JM, et al. The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality. Coron Artery Dis. 2014 Aug;25(5):392-8. DOI: 10.1097/MCA.000000000000010810.1097/MCA.000000000000010824625688
- 3. Monassier JP. Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part I: Basic considerations. Arch Cardiovasc Dis. 2008;101(7-8):491-500. DOI: 10.1016/j.acvd.2008.06.01410.1016/j.acvd.2008.06.01418848692
- 4. Hernandez-Resendiz S, Chinda K, Ong SB, Cabrera-Fuentes H, Zazueta C, Hausenloy DJ. The role of redox dysregulation in the inflammatory response to acute myocardial ischaemia-reperfusion injury - adding fuel to the fire. Curr Med Chem. 2017;25(11):1275-93. DOI: 10.2174/092986732466617032910061910.2174/092986732466617032910061928356034
- 5. Weir RA, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail. 2013;6(3):492-8. DOI: 10.1161/CIRCHEART-FAILURE.112.000146
- 6. Miller AM, Liew FY. The IL-33/ST2 pathway-A new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011;131(2):179-86. DOI: 10.1016/j. pharmthera.2011.02.005
- 7. Zhang R, Zhang Y, An T, Guo X, Yin S, Wang Y, et al. Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. Biomark Med. 2015;9(5):433-41. DOI: 10.2217/bmm.15.1210.2217/bmm.15.1225985174
- 8. Weir RA, Miller AM, Murphy GE, Clements S, Steed-man T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243-50. DOI: 10.1016/j. jacc.2009.08.047
- 9. Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. [2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(10):766-83.
- 10. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consulation; WHO: Geneva, Switzerland, 2006.
- 11. Jespersen L, Hvelplund A, Abildstrøm SZ, Pedersen F, Galatius S, Madsen JK, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33(6):734-44. DOI: 10.1093/eurheartj/ehr33110.1093/eurheartj/ehr33121911339
- 12. Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2017;15(3):203-14. DOI: 10.1038/nrcardio.2017.16110.1038/nrcardio.2017.16129143812
- 13. Luger D, Lipinski MJ, Westman PC, Glover DK, Dimastromatteo J, Frias JC, et al. Intravenously Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy. Circ Res. 2017;120(10):1598-613. DOI: 10.1161/CIRCRESAHA.117.31059910.1161/CIRCRESAHA.117.31059928232595
- 14. Lu H, Liu Y, Wang D, Wang L, Zhou H, Xu G, et al. Galectin-3 regulates metastatic capabilities and chemo-therapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway. Tumour Bio. 2016;37(8):11469-77. DOI: 10.1007/s13277-016-5004-310.1007/s13277-016-5004-327012551
- 15. Luo R, Sun X, Shen F, Hong B, Wang Z. Effects of High-Dose Rosuvastatin on Ventricular Remodelling and Cardiac Function in ST-Segment Elevation Myocardial Infarction. Drug Des Devel The. 2020;14(2):3891-8. DOI: 10.2147/DDDT.S25494810.2147/DDDT.S254948752015233061295
- 16. Arora G, Bittner V. Chest pain characteristics and gender in the early diagnosis of acute myocardial infarction. Curr Cardiol Rep. 2015;17(2):5. DOI: 10.1007/s11886-014-0557-510.1007/s11886-014-0557-525618302
- 17. Binas D, Daniel H, Richter A, Ruppert V, Schlüter KD, Schieffer B, et al. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart. 2018;5(1):e000750. DOI: 10.1136/openhrt-2017-00075010.1136/openhrt-2017-000750584540429531765
- 18. Rivera-Caravaca JM, Teruel-Montoya R, Roldán V, Cifuentes-Riquelme R, Crespo-Matas JA, de Los Reyes-García AM, et al. Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. J Clin Med. 2020;9(11):3645. DOI: 10.3390/jcm911364510.3390/jcm9113645769812433198388
- 19. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230(1):160-71. DOI: 10.1111/j.1600-065X.2009.00794.x10.1111/j.1600-065X.2009.00794.x19594635
- 20. Lupu A, Lupu S, Agoston-Coldea L. Is galectin-3 a promoter of ventricular dysfunction? Rev Romana Med Lab. 2018;26(1):21-36. DOI: 10.2478/rrlm-2018-000110.2478/rrlm-2018-0001